How many institutions own QCLS stock?

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own QCLS shares is 21, representing 9.59% of the company's common stock.

Who are the major shareholders selling Q/C Technologies, Inc. stock?

BANK OF AMERICA CORP /DE/, in the last quarter, reduced its stake in QCLS by -100% restricting it's holding to 0 shares of worth nearly -. WELLS FARGO & COMPANY/MN also lessened -100% of the QCLS shares from its portfolio, reducing its holding to 0 shares of worth -. MORGAN STANLEY also shunned QCLS shares holding by -100% last quarter which brought its holding to 0 shares worth -.

Investors who are buying QCLS stock?

As per its latest 13F filing, ADAR1 CAPITAL MANAGEMENT, LLC increased its stake in QCLS by 100% in the last quarter. The institutional holder raised its holding to 50 thousand shares having worth more than $172.50K. GEODE CAPITAL MANAGEMENT, LLC also added 62.01% more shares of QCLS to its portfolio, raising its holding to 47.39 thousand shares of worth $163.50K. JANE STREET GROUP, LLC also increased its QCLS shares holding by 211.68% which brought its holding to 126.19 thousand shares worth $435.35K.

QCLS's major insiders: who are they?

The insider with the most stakes in QCLS is PharmaCyte Biotech, Inc. , 10 percent owner at the company. Additionally, QCLS stock is highly held by director Voss Chelsea Sierra and N/A N/A among others.

Did an insider recently sell QCLS stock?

Company executives, directors, and other insiders own 4.35% percent of Q/C Technologies, Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which QCLS insiders have sold stock, totaling 0 shares. Insiders that have sold shares include .

Which insider recently purchased QCLS stock?

There have been 1 transaction(s) during the past 6-months in which Q/C Technologies, Inc. insiders have bought stock, totalling 1753 shares

How much of QCLS does insiders own?

Around 61.56K Q/C Technologies, Inc. shares are held by insiders, which represents about 4.35% of QCLS stock.

Who is the insider with the largest stake?

QCLS 10 percent owner, PharmaCyte Biotech, Inc. holds the largest portfolio of the company's shares. QCLS shares owned by PharmaCyte total nearly 889.87 thousand.

Which institution holds the most shares in QCLS?

ADAR1 CAPITAL MANAGEMENT, LLC is the largest institutional owner in QCLS which holds 50 thousand shares worth $172.50K or 0.62% of the total QCLS shares outstanding followed by GEODE CAPITAL MANAGEMENT, LLC with ownership of 47.39 thousand shares representing 0.59% of the QCLS ownership. DIMENSIONAL FUND ADVISORS LP is the third largest stakeholder with 19.06 thousand shares or 0.24% of the ownership worth more than $65.75K.

Is Q/C Technologies, Inc. stock optionable?

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the QCLS is concerned, it is a stock which is not optionable.

Is there a short position on QCLS's shares?

Number of QCLS shares short is null. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

About how many outstanding QCLS shares are there?

As of today, null shares of QCLS are outstanding.

Is there many float in QCLS stock?

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, QCLS has null shares in float.

QCLS short ratio: what is it?

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for QCLS is null.

Stock Ideas

QCLS Stock Ownership Breakdown

NASDAQ : QCLS

Q/C Technologies

$3.79

-0.06-1.56%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stock Outstanding Shares

Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.

ShortableYes

OptionableNo

Short Percent Of Outstanding SharesN/A

Short Percent Of FloatN/A

Shares OutstandingN/A

Shares FloatN/A

Shares ShortN/A

Short RatioN/A

N/A

Short % of Float

N/A

Short % of Shares Outstanding

Market Insider

Investors cannot turn a blind eye to insiders as well as institutional ownership. They need to follow insider trades to determine the direction the stock is likely to take.

Major Holders Summary

4.35% Percentage of Shares held by All Insiders

9.59% Percentage of Shares held by All Institutions

10.02% Percentage of Float held by Institutions

Number of Institutions Holding Shares

Institutional Ownership

About 9.59% of QCLS shares are held by financial institutions. ADAR1 CAPITAL MANAGEMENT, LLC is the top corporate investor, holding 50K shares valued at $172.50K. A 0.62% stake in Q/C Technologies, Inc. is owned by the company. GEODE CAPITAL MANAGEMENT, LLC owns 47.39K shares valued at $163.50K, which translates its holding of 0.59% of the stake in the company.

Date	Holder	% Stake	Shares Held	Total Value ($)	Shares	% Change in Portfolio
Mar 31, 2026	ADAR1 CAPITAL MANAGEMENT, LLC	0.62%	50K	172.5K	50K	+100.00%
Mar 31, 2026	GEODE CAPITAL MANAGEMENT, LLC	0.59%	47.39K	163.5K	18.14K	+62.01%
Mar 31, 2026	DIMENSIONAL FUND ADVISORS LP	0.24%	19.06K	65.75K	0	0
Mar 31, 2026	QUINN OPPORTUNITY PARTNERS LLC	2.62%	211.39K	729.3K	0	0
Mar 31, 2026	JANE STREET GROUP, LLC	1.57%	126.19K	435.35K	85.7K	+211.68%
Mar 31, 2026	UBS GROUP AG	0.97%	77.99K	269.06K	60.56K	+347.57%
Mar 31, 2026	HRT FINANCIAL LP	0.28%	22.4K	77K	22.4K	+100.00%
Mar 31, 2026		0.47%	37.51K	129.41K	37.51K	+100.00%
Mar 31, 2026	BANK OF AMERICA CORP /DE/	0%	0	-	-25	-100.00%
Mar 31, 2026	WELLS FARGO & COMPANY/MN	0%	0	-	-1	-100.00%
Mar 31, 2026	MORGAN STANLEY	0%	0	-	-20	-100.00%
Mar 31, 2026	VANGUARD FIDUCIARY TRUST CO	0.19%	15.56K	53.67K	15.56K	+100.00%
Mar 31, 2026	STATE STREET CORP	0.16%	12.91K	44.52K	12.91K	+100.00%
Mar 31, 2026	PIN OAK INVESTMENT ADVISORS INC	0.04%	3.5K	12K	3.5K	+100.00%
Mar 31, 2026	SUNBELT SECURITIES, INC.	0.02%	1.75K	6.04K	1.75K	+100.00%
Mar 31, 2026	TOWER RESEARCH CAPITAL LLC (TRC)	0.02%	1.59K	5.5K	1.36K	+577.87%
Mar 31, 2026	BNP PARIBAS ARBITRAGE, SNC	0%	300	1.04K	-900	-75.00%
Mar 31, 2026	BLACKROCK, INC.	0%	19	66	0	0
Mar 31, 2026	JONES FINANCIAL COMPANIES LLLP	0%	2	7	0	0
Mar 31, 2026	BRYN MAWR TRUST CO	0%	1	3	0	0
Mar 31, 2026	GROUP ONE TRADING, L.P.	0%	0	-	-2	-100.00%
Mar 31, 2026	VIRTU FINANCIAL LLC	0%	0	-	-35.38K	-100.00%
Mar 31, 2026	PRIVATE ADVISOR GROUP, LLC	0%	0	-	-333.83K	-100.00%
Mar 31, 2026	ENGINEERS GATE MANAGER LP	0%	0	-	-11.33K	-100.00%

Insiders

Among the QCLS insiders holding of 4.35% of the stake in company, PHARMACYTE BIOTECH, INC., 10 percent owner, holds the largest shares of 889.87K. VOSS CHELSEA SIERRA, director, is the second largest QCLS insider with ownership of 61.56K shares. , , stands third with possession of - shares of that stake.

Insiders	Designation	Shares Held
PHARMACYTE BIOTECH, INC.	10 percent owner	889.87K
VOSS CHELSEA SIERRA	director	61.56K

Buying/Selling by Insiders

Date	Insider	Type	Cost	Shares	Value ($)	Shares Total
Mar 30, 2026	VOSS CHELSEA SIERRA	PURCHASE	3.15	1.75K	5.52K	61.56K
Nov 14, 2025	PHARMACYTE BIOTECH, INC.	PURCHASE	0.00	889.87K	-	889.87K
Sep 04, 2025	PHARMACYTE BIOTECH, INC.	PURCHASE	0.00	889.87K	-	889.87K

Insider Transaction Summary (6 Months)

SHARESTRANS

PURCHASE1.75K1

SALES00

NET SHARES1.75K1

SHARES HELD61.56K1

% NET SHARES-97.15%0%

Frequently Asked Questions

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.